Angiodynamics completes patient enrollment in apex-av study assessing alphavac f1885 system in treatment of pulmonary embolism

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the acute pulmonary embolism extraction trial with the alphavac system (apex-av). apex-av is a clinical study aimed at evaluating the safety and efficacy of the company's alph.
ANGO Ratings Summary
ANGO Quant Ranking